Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
MEDIROM Healthcare Technologies Cash Conversion Cycle Related Terms
MEDIROM Healthcare Technologies Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRM vs EJH, CLIK, DROR: Cash Conversion Cycle Comparison
For the Personal Services subindustry, MEDIROM Healthcare Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDIROM Healthcare Technologies Cash Conversion Cycle vs Personal Services Industry
For the Personal Services industry and Consumer Cyclical sector, MEDIROM Healthcare Technologies's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where MEDIROM Healthcare Technologies's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDIROM Healthcare Technologies (MRM) has a Cash Conversion Cycle of -23.70 as of Jun. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on MEDIROM Healthcare Technologies and its competitors.
Is MEDIROM Healthcare Technologies' Cash Conversion Cycle too high?
MEDIROM Healthcare Technologies' current Cash Conversion Cycle is -23.70. Overall, MEDIROM Healthcare Technologies has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MEDIROM Healthcare Technologies' Cash Conversion Cycle compare to EJH and CLIK?
MEDIROM Healthcare Technologies' Cash Conversion Cycle of -23.70 can be compared against companies in the Personal Services industry. The industry median Cash Conversion Cycle is 20.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Personal Services company?
The median Cash Conversion Cycle among Personal Services companies is 20.66, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on MEDIROM Healthcare Technologies and its competitors. For the Personal Services industry, the median Cash Conversion Cycle is 20.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDIROM Healthcare Technologies's current Cash Conversion Cycle is -23.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDIROM Healthcare Technologies stock overvalued right now?
Based on GuruFocus' analysis, MEDIROM Healthcare Technologies (MRM) is currently considered Possible Value Trap. The stock's GF Value™ is $4.08, compared to a current price of $0.95 — trading 76.7% below its estimated fair value. The current Cash Conversion Cycle is -23.70. MEDIROM Healthcare Technologies' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For MEDIROM Healthcare Technologies (MRM), the current Cash Conversion Cycle is -23.70 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDIROM Healthcare Technologies (MRM) Overvalued in 2026?
Based on GuruFocus' analysis, MEDIROM Healthcare Technologies stock appears to be undervalued.
The current stock price of $0.95 is trading 76.7% below its estimated GF Value™ of $4.08.
GuruFocus considers MEDIROM Healthcare Technologies to be Possible Value Trap.
Key valuation signals for MRM:
Cash Conversion Cycle: -23.70
GF Value™: $4.08 vs. price of $0.95 (76.7% below fair value)
No single metric tells the full story. See the MRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDIROM Healthcare Technologies Business Description
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
53GF Score
Get the complete analysis for MRM
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRM has been successfully added to your 
